Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (161-170 of 257) with videos related to

Pageof 26
Sort By:
The New England Journal of Medicine|May 11, 2012
Lenalidomide maintenance after stem-cell transplantation for multiple myelomaMichel Attal, Valerie Lauwers-Cances, Gerald Marit, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
Journal of Cancer|March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationGuillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Cancer Medicine|May 31, 2019
Response to pneumococcal vaccination in multiple myelomaLoïc Renaud, Susanna Schraen, Guillemette Fouquet, et al.
British Journal of Haematology|January 21, 2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trialJin Lu, Jae H Lee, Shang-Yi Huang, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Pageof 26

Showing results (161-170 of 257) with videos related to

Sort By:
Pageof 26
The New England Journal of Medicine|May 11, 2012
Lenalidomide maintenance after stem-cell transplantation for multiple myelomaMichel Attal, Valerie Lauwers-Cances, Gerald Marit, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
Journal of Cancer|March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationGuillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
The Lancet. Oncology|May 18, 2019
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trialPaul G Richardson, Albert Oriol, Meral Beksac, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Cancer Medicine|May 31, 2019
Response to pneumococcal vaccination in multiple myelomaLoïc Renaud, Susanna Schraen, Guillemette Fouquet, et al.
British Journal of Haematology|January 21, 2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trialJin Lu, Jae H Lee, Shang-Yi Huang, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Pageof 26